Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,552.00-0.29%ETH$2,697.47-0.58%GOLD$4,187.80+0.02%OIL$90.23+0.88%
Smart Investors Daily
SID Premium
OK

NASDAQ · OKUR

OnKure Therapeutics, Inc.

Healthcare · Biotechnology

$2.63

Down-$0.17 (-6.46%)

Updated Oct 7, 2026, 12:41 AM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
44.44M
P/E ratio
-6.67
Dividend yield
0.00%
52-week range
$2.23 – $5.38
Volume
632.34K
Avg. volume
131.89K

Price performance · OKUR

OKUR price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

OKUR closed at $2.63 after 20 trading sessions, down 22.65% for the selected period.

Last close
$2.63
Period change
-22.65%
Period low
$2.54
Period high
$3.40
Daily close
View OHLC price history
OKUR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$2.56$2.67$2.42$2.63632.34K
Oct 2, 2026$2.57$2.61$2.46$2.56526.93K
Oct 1, 2026$2.72$2.825$2.50$2.542.08M
Sep 30, 2026$2.63$2.79$2.50$2.725831.41K
Sep 29, 2026$2.78$2.80$2.47$2.60339.83K
Sep 28, 2026$2.87$2.879$2.60$2.76442.23K
Sep 25, 2026$2.93$3.00$2.86$2.9091.43K
Sep 24, 2026$2.96$3.05$2.88$2.93149.72K
Sep 23, 2026$3.09$3.24$2.90$2.94149.75K
Sep 22, 2026$3.06$3.11$2.91$3.10200.81K
Sep 21, 2026$2.95$3.10$2.92$3.06166.72K
Sep 18, 2026$2.96$3.08$2.91$2.95223.09K
Sep 17, 2026$2.94$3.02$2.82$2.96180.99K
Sep 16, 2026$2.93$3.005$2.84$2.8883.87K
Sep 15, 2026$2.98$2.98$2.815$2.93171.1K
Sep 14, 2026$3.11$3.14$2.978$3.00105.16K
Sep 11, 2026$3.31$3.33$2.98$3.10253.65K
Sep 10, 2026$3.36$3.42$3.24$3.27168.52K
Sep 9, 2026$3.38$3.4899$3.319$3.3880.09K
Sep 8, 2026$3.55$3.90$3.34$3.40115.01K

Latest OKUR news

The latest Smart Investors Daily articles mentioning OKUR.

Stock researchCompany · Overview

OKUR research

Overview

Company profile and research snapshot.

Company profile

OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$35.00
Implied upside
—
Analysts
—
OKUR recent ratings
DateFirmRatingTarget
Aug 14, 2026OppenheimerOutperform—
Jul 20, 2026HC Wainwright & Co.Buy—
Mar 16, 2026HC Wainwright & Co.Buy—
Aug 26, 2025HC Wainwright & Co.Buy—
Mar 18, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 31, 2026

OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference

BOULDER, Colo., Aug. 31, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that senior management will participate in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference being held in New York on September 14 – 16, 2026. The OnKure management team will host one-on-one meetings during the conference. Interested investors should contact their Morgan

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By